Are nutritional supplements or dietary interventions safe and effective for patients with hair loss?
In this systematic review of 30 studies of nutritional interventions, the highest-quality evidence suggests the potential effectiveness of Viviscal, Nourkrin, Nutrafol, Lamdapil, Pantogar, Capsaicin and isoflavone, omega 3 and 6 with antioxidants, apple nutraceutical, total glucosides of paeony and compound glycyrrhizin tablets, zinc, tocotrienol, and pumpkin seed oil. No data for dietary interventions were identified.
The findings of this systematic review indicate that nutritional interventions may benefit select patients with hair loss, and although few adverse events were reported, physicians should engage in shared decision-making with patients given the lack of federal oversight of these regimens.
Despite the widespread use of nutritional supplements and dietary interventions for treating hair loss, the safety and effectiveness of available products remain unclear.
To evaluate and compile the findings of all dietary and nutritional interventions for treatment of hair loss among individuals without a known baseline nutritional deficiency.
The MEDLINE, Embase, and CINAHL databases were searched from inception through October 20, 2021, to identify articles written in English with original findings from investigations of dietary and nutritional interventions in individuals with alopecia or hair loss without a known baseline nutritional deficiency. Quality was assessed with Oxford Centre for Evidence Based Medicine criteria. Outcomes of interest were disease course, both objectively and subjectively measured. Data were evaluated from January 3 to 11, 2022.
The database searches yielded 6347 citations to which 11 articles from reference lists were added. Of this total, 30 articles were included: 17 randomized clinical trials (RCTs), 11 clinical studies (non-RCT), and 2 case series studies. No diet-based interventional studies met inclusion criteria. Studies of nutritional interventions with the highest-quality evidence showed the potential benefit of Viviscal, Nourkrin, Nutrafol, Lamdapil, Pantogar, capsaicin and isoflavone, omegas 3 and 6 with antioxidants, apple nutraceutical, total glucosides of paeony and compound glycyrrhizin tablets, zinc, tocotrienol, and pumpkin seed oil. Kimchi and cheonggukjang, vitamin D3, and Forti5 had low-quality evidence for disease course improvement. Adverse effects were rare and mild for all the therapies evaluated.
Conclusions and Relevance
The findings of this systematic review should be interpreted in the context of each study’s design; however, this work suggests a potential role for nutritional supplements in the treatment of hair loss. Physicians should engage in shared decision-making by covering the potential risks and benefits of these treatments with patients experiencing hair loss. Future research should focus on larger RCTs with active comparators.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: September 18, 2022.
Published Online: November 30, 2022. doi:10.1001/jamadermatol.2022.4867
Corresponding Author: Arash Mostaghimi, MD, MPA, MPH, Department of Dermatology, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115 (email@example.com).
Author Contributions: Ms Drake and Dr Mostaghimi had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Reyes-Hadsall, Heinrich, Huang, Mostaghimi.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Drake, Reyes-Hadsall, Martinez, Heinrich, Mostaghimi.
Critical revision of the manuscript for important intellectual content: Drake, Reyes-Hadsall, Huang, Mostaghimi.
Statistical analysis: Drake, Martinez.
Administrative, technical, or material support: Drake, Reyes-Hadsall, Martinez, Heinrich, Mostaghimi.
Supervision: Huang, Mostaghimi.
Conflict of Interest Disclosures: Dr Huang reported personal fees from Concert and Pfizer outside the submitted work; holding patents for ALTO, BETA, and BELA licensed; and participation in alopecia-related clinical trials by Incyte, Lilly, Concert, and Aclaris, all outside the submitted work. Dr Mostaghimi reported consulting fees from Pfizer, Concert, Lilly, Hims and Hers, Equillium, AbbVie, Digital Diagnostics, and Bioniz, and grants from Pfizer, all outside the submitted work. No other disclosures were reported.
Disclaimer: Dr Arash Mostaghimi is an Associate Editor of JAMA Dermatology but was not involved in any of the decisions regarding review of the manuscript or its acceptance.
You currently have no searches saved.
You currently have no courses saved.